Skip to main content

Advertisement

SpringerLink
Log in

Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease

  • Nephrology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Asprosin was a newly identified secreted hormone which could induce hepatic glucose release. Since asprosin closely associated with the risk factors of diabetic kidney disease (DKD), including hyperglycemia, insulin resistance and inflammation, the present study aimed to investigate the relationship between circulating asprosin levels and the early stage of DKD.

Methods

30 subjects with normal glucose tolerance (NGT), 42 type 2 diabetes (T2DM) patients without DKD and 33 T2DM patients with early stage of DKD were recruited. Early stage of DKD was defined as two consecutive measurements of urinary albumin-to-creatinine ratio (UACR) 30–299 mg/g and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2. Multiple linear regression analysis was conducted to explore the associations of circulating asprosin levels with eGFR and UACR. Multiple logistic regression analysis was used to determine the association of circulating asprosin levels with the early stage of DKD.

Results

Circulating asprosin levels in Non-DKD and DKD groups were significantly higher than that in NGT group and the DKD group showed the highest levels. Circulating asprosin levels negatively correlated with eGFR (r = − 0.311, P = 0.007) and positively correlated with UACR (r = 0.345, P = 0.002) in T2DM patients. Even after multivariable adjustment, circulating asprosin levels were closely associated with eGFR and UACR and significantly increased ORs for early stage of DKD (OR = 3.973, P = 0.001).

Conclusion

Circulating asprosin levels were increased in T2DM and associated with the early stage of DKD. The specific role of asprosin in DKD needs further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tuttle KR, Bakris GL, Bilous RW et al (2014) Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37:2864–2883

    Article  Google Scholar 

  2. Wouters OJ, O'Donoghue DJ, Ritchie J et al (2015) Early chronic kidney disease: diagnosis, management and models of care. Nat Rev Nephrol 11:491–502

    Article  Google Scholar 

  3. Tangri N, Kitsios GD, Inker LA et al (2013) Risk prediction models for patients with chronic kidney disease: a systematic review. Ann Intern Med 158:596–603

    Article  Google Scholar 

  4. Lin YC, Chang YH, Yang SY et al (2018) Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc 117:662–675

    Article  CAS  Google Scholar 

  5. Furuya F, Ishii T, Kitamura K (2019) Chronic inflammation and progression of diabetic kidney disease. Contrib Nephrol 198:33–39

    Article  CAS  Google Scholar 

  6. Romere C, Duerrschmid C, Bournat J et al (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165:566–579

    Article  CAS  Google Scholar 

  7. Greenhill C (2016) Liver: Asprosin—new hormone involved in hepatic glucose release. Nat Rev Endocrinol 12:312

    Article  CAS  Google Scholar 

  8. Zhang L, Chen C, Zhou N et al (2019) Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 489:183–188

    Article  CAS  Google Scholar 

  9. Wang Y, Qu H, Xiong X et al (2018) Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm 2018:9471583

    PubMed  PubMed Central  Google Scholar 

  10. Li X, Liao M, Shen R et al (2018) Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators Inflamm 2018:7375294

    PubMed  PubMed Central  Google Scholar 

  11. Zhang X, Jiang H, Ma X, Wu H (2019) Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. https://doi.org/10.1111/jdi.13148

    Article  PubMed  PubMed Central  Google Scholar 

  12. American Diabetes Association (2020) Standards of Medical Care in Diabetes-2020. Diabetes Care 43(Suppl 1):S1–S212

    Google Scholar 

  13. Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

    Article  Google Scholar 

  14. Li E, Shan H, Chen L et al (2019) OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab 30:319–328

    Article  CAS  Google Scholar 

  15. Lee T, Yun S, Jeong JH et al (2019) Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol 486:96–104

    Article  CAS  Google Scholar 

  16. Jung TW, Kim HC, Kim HU et al (2019) Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. J Cell Physiol 234:20888–20899

    Article  CAS  Google Scholar 

  17. Wang CY, Lin TA, Liu KH et al (2019) Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes (Lond) 43:1019–1025

    Article  CAS  Google Scholar 

  18. Ugur K, Aydin S (2019) Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol 2019:2521096

    Article  Google Scholar 

  19. Wang M, Yin C, Wang L et al (2019) Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. https://doi.org/10.1159/000503808

    Article  PubMed  Google Scholar 

  20. Long W, Xie X, Du C et al (2019) Decreased circulating levels of asprosin in obese children. Horm Res Paediatr 91:271–277

    Article  CAS  Google Scholar 

  21. Duerrschmid C, He Y, Wang C et al (2017) Asprosin is a centrally acting orexigenic hormone. Nat Med 23:1444–1453

    Article  CAS  Google Scholar 

  22. Alan M, Gurlek B, Yilmaz A et al (2019) Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 35:220–223

    Article  CAS  Google Scholar 

  23. Chang CL, Huang SY, Hsu YC, Chin TH, Soong YK (2019) The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep 9:6447

    Article  Google Scholar 

  24. Ko JR, Seo DY, Kim TN et al (2019) Aerobic exercise training decreases hepatic asprosin in diabetic rats. J Clin Med 8:E666

    Article  Google Scholar 

  25. Wiecek M, Szymura J, Maciejczyk M, Kantorowicz M, Szygula Z (2018) Acute anaerobic exercise affects the secretion of asprosin, irisin, and other cytokines—a comparison between sexes. Front Physiol 9:1782

    Article  Google Scholar 

Download references

Acknowledgements

We thank all the staff at the Health Management Center of Shandong Provincial Qianfoshan Hospital.

Author information

Authors and Affiliations

  1. Health Management Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated Hospital of Shandong First Medical University, Jinan, 250012, Shandong, China

    Hongyu Zhang, Wenqi Hu & Guang Zhang

Authors
  1. Hongyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wenqi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have contributed significantly. GZ mainly designed the study and wrote the manuscript. HYZ and WQH mainly collected the data and conducted analyses.

Corresponding author

Correspondence to Guang Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the ethics committee of Shandong Provincial Qianfoshan Hospital and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Written informed consent was obtained from each patient before the study began.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (XLS 51 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, H., Hu, W. & Zhang, G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol 52, 1517–1522 (2020). https://doi.org/10.1007/s11255-020-02509-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-020-02509-8

Keywords

Search

Navigation